Senior Scientist, Genome Editing

Company Description

Helex is a therapeutics company developing a new class of targeted medicines for genetic kidney diseases using its proprietary LNP drug delivery and AI-based drug design platforms. With a world-class team of scientists and drug developers, Helex operates from ASPIRE BioNEST, Hyderabad, India, and New York, USA, and is supported by Bayer Co.Lab Cambridge. 

Role Description

This is a full-time on-site role located in Hyderabad, India. A Senior Scientist in Gene Editing at Helex will be responsible for leading research and development projects to advance the company's gene-editing technologies for renal applications. The day-to-day tasks will include designing and conducting experiments, analyzing data, collaborating with cross-functional teams, and staying up to date with the latest advancements in genome editing and genetic medicine.

Qualifications & Experience

• PhD in Genetics, Molecular Biology, Biotechnology, or a related field, or relevant Master's with exceptional industry experience (over 10 years)
• 3-5 years of experience with gene editing techniques such as CRISPR/Cas9 or similar technologies, in both cell and animal models
• Strong expertise in

  i

  n vivo studies involving gene editing, including animal handling, dosing, and tissue analysis
• Proficiency in molecular and cellular biology assays (PCR, qPCR, ddPCR, ELISA, Western blot, flow cytometry, immunostaining).
• Experience in designing studies such as toxicology and PK/PD experiments, and executing internally and in collaboration with CROs
• Familiarity with GLP practices, IND-enabling workflows, and regulatory expectations for gene editing programs
• Excellent analytical skills, along with the ability to interpret complex data
• Ability to work collaboratively in a multi-disciplinary team environment
• Publications in peer-reviewed journals demonstrating impactful research
• Background in renal biology and kidney disease research preferred
• Experience in nanoparticle delivery systems and lipid nanoparticles is preferred, but not compulsory